文献速递炎症性肠病

维得利珠单抗对溃疡性结肠炎患者健康相关生活质量的影响:随机GEMINI 1试验结果

Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial.
PubMed 文献 · Aliment Pharmacol Ther · 2016-11-17

基于GEMINI 1研究维持期数据,分析维得利珠单抗与安慰剂组从基线至第52周在IBDQ、SF-36和EQ-5D三个健康相关生活质量量表上的变化差异。维得利珠单抗组在IBDQ、EQ-5D视觉模拟量表和EQ-5D效用评分上的改善幅度大于安慰剂组(152%-201%),达到最小临床重要差异阈值的患者比例更高(6.9%-19.9%)。基线疾病活动度较低且无既往肿瘤坏死因子拮抗剂失败的患者HRQL改善更明显。

要点

  • 维得利珠单抗组第52周IBDQ、EQ-5D VAS和EQ-5D效用评分改善幅度为安慰剂组的152%-201%。
  • 维得利珠单抗组达到MCID阈值的患者比例较安慰剂组高6.9%-19.9%。
  • 127例基于完整Mayo评分临床缓解的患者中>80%同时达到IBDQ缓解。

核心结论

  • 维得利珠单抗治疗与安慰剂相比在HRQL指标上带来显著改善。
  • 基线疾病活动度较低且无既往TNF拮抗剂失败的患者获益更大。

研究设计与样本

  • 研究使用GEMINI 1随机试验的维持期数据,采用协方差分析模型计算维得利珠单抗组与安慰剂组从基线至第52周在IBDQ、SF-36和EQ-5D三个HRQL工具上变化的平均差异。
  • 比较总体人群和临床重要亚组中达到各工具最小临床重要差异阈值的患者比例,并检查基于完整Mayo评分临床缓解与基于IBDQ评分缓解之间的一致性。

主要发现

  • 与安慰剂组相比,维得利珠单抗组在IBDQ、EQ-5D视觉模拟量表和EQ-5D效用评分上的改善幅度更大(152%-201%)。
  • 维得利珠单抗组达到所有工具MCID阈值的患者比例高于安慰剂组(6.9%-19.9%)。
  • 基线疾病活动度较低和无既往TNF拮抗剂失败的患者HRQL改善更大。
  • 127例基于完整Mayo评分临床缓解的患者中,>80%同时达到IBDQ缓解;150例IBDQ缓解患者中>70%达到临床缓解。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Health-related quality of life (HRQL) is often diminished in patients with ulcerative colitis. AIM: To evaluate the effects of vedolizumab on HRQL in patients with ulcerative colitis. METHODS: Using maintenance phase data from the GEMINI 1 study, an analysis of covariance model was used to calculate mean differences between the vedolizumab and placebo groups in changes from baseline to week 52 for 3 HRQL instruments: The Inflammatory Bowel Disease Questionnaire (IBDQ), 36-Item Short Form Health Survey (SF-36), and EQ-5D. Proportions of patients meeting minimal clinically important difference (MCID) thresholds for changes on these instruments were compared between treatment groups for the overall population and for clinically important subgroups. Concordance between clinical remission and remission defined using IBDQ scores was examined. RESULTS: Compared with placebo-treated patients, vedolizumab-treated patients had greater improvements (152-201%) in IBDQ, EQ-5D visual analogue scale (VAS), and EQ-5D utility scores. Greater proportions (6.9-19.9%) of vedolizumab-treated patients than placebo-treated patients met MCID thresholds for all the instruments. Vedolizumab-treated patients with lower baseline disease activity and those without prior tumour necrosis factor (TNF) antagonist failure had greater HRQL improvements. Among 127 patients with clinical remission based on complete Mayo Clinic scores, >80% also had IBDQ remission; >70% of the 150 patients with IBDQ remission demonstrated clinical remission. CONCLUSIONS: Vedolizumab therapy was associated with significant improvements in HRQL measures compared with placebo. Benefits were greater in patients with lower disease activity and no prior TNF antagonist failure.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Feagan BG, Patel H, Colombel JF, et al. Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial. Aliment Pharmacol Ther. 2016. PMID: 27859410. doi:10.1111/apt.13852

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。